NEUWAVE Flexible Probe Study #2
Status: | Not yet recruiting |
---|---|
Conditions: | Lung Cancer, Lung Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/28/2019 |
Start Date: | July 1, 2019 |
End Date: | May 31, 2021 |
Contact: | Bertha Fearon |
Email: | bfearon1@its.jnj.com |
Phone: | 908-524-3749 |
A Multicenter Study of the NEUWAVE Flex Microwave Ablation System in the Ablation of Secondary Soft Tissue Lesions of the Lung
Patients with medically inoperable and operable secondary soft tissue lesion(s) of the lung
will have transbronchial microwave ablation performed using cone beam CT for probe guidance
and confirmation.
will have transbronchial microwave ablation performed using cone beam CT for probe guidance
and confirmation.
Adult patients with medically inoperable and operable secondary soft tissue lesion(s) of the
lung less than 2cm will undergo transbronchial microwave ablation performed by an
interventional pulmonologist or thoracic surgeon using cone beam CT imaging for probe
guidance and confirmation on ablation outcome. All treated patients will be followed for one
year following the ablation procedure for efficacy and safety.
lung less than 2cm will undergo transbronchial microwave ablation performed by an
interventional pulmonologist or thoracic surgeon using cone beam CT imaging for probe
guidance and confirmation on ablation outcome. All treated patients will be followed for one
year following the ablation procedure for efficacy and safety.
Inclusion Criteria:
1. Signed Informed Consent
2. Patients greater or equal to 18 years of age
3. Performance status 0-2 (Eastern Cooperative Oncology Group classification [ECOG])
4. Willing to fulfill all follow-up visit requirements
5. Medically inoperable and operable secondary soft tissue lesion(s) of the lung
6. A maximum of two ipsilateral soft tissue lesions less than or equal to 2cm in the
outer two-thirds of the lung and not closer than 1cm to the pleura. Lesion size must
be measured with at least 2-dimensional imaging.
Exclusion Criteria:
1. Scheduled concurrent procedure for the target soft tissue lesion(s) other than those
that are lung-related
2. Pregnant or breastfeeding
3. Physical or psychological condition that would impair study participation
4. Patients with uncorrectable coagulopathy at the time of screening
5. Patient with implantable devices, including pacemakers or other electronic implants
6. Prior pneumonectomy or bronchiectasis
7. Severe neuromuscular disease
8. Patient count less than or equal to 50,000/mm cubed
9. ASA (American Society of Anesthesiologists) score of greater than or equal to 4
10. Inability to tolerate anesthesia
11. Expected survival less than 6 months
12. Clinically significant hypertension
13. Chronic, continuous ventilator support, which uses bi-level positive airway pressure
(PAP) to improve lung function for severe conditions (however, intermittent PAP, for
non-pulmonary conditions, such as sleep apnea, is permitted)
14. Endobronchial soft tissue lesions proximal to the segmental airways
15. Imaging findings of active pulmonary infection
16. The patient was judged unsuitable for study participation by the Investigator for any
other reason.
We found this trial at
5
sites
425 East 61st Street
New York, New York 10065
New York, New York 10065
Principal Investigator: Bradley Pua
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Thomas Gildea
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Click here to add this to my saved trials
Pinehurst, North Carolina 28374
Principal Investigator: Michael Pritchett
Click here to add this to my saved trials
Click here to add this to my saved trials